SIGA Technologies (NASDAQ:SIGA) Reaches New 1-Year High at $23.00
SIGA Technologies (NASDAQ:SIGA) Reaches New 1-Year High at $23.00
A number of large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC purchased a new stake in SIGA Technologies in the 4th quarter worth $3,517,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of SIGA Technologies during the second quarter worth approximately $3,346,000. Renaissance Technologies LLC increased its holdings in SIGA Technologies by 44.9% during the fourth quarter. Renaissance Technologies LLC now owns 893,504 shares of the company's stock valued at $6,719,000 after buying an additional 276,814 shares during the period. Kempen Capital Management N.V. grew its holdings in SIGA Technologies by 19.5% in the first quarter. Kempen Capital Management N.V. now owns 1,376,982 shares of the company's stock worth $9,763,000 after purchasing an additional 224,423 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in SIGA Technologies in the first quarter worth $1,133,000. 34.52% of the stock is currently owned by institutional investors. SIGA Technologies, Inc. (NASDAQ:SIGA – Get Rating) hit a new 52-week high on Friday . The company traded as high as $23.00 and last traded at $22.26, with a volume of 250343 shares. The stock had previously closed at $19.47.
上週五，SIGA科技公司(納斯達克代碼：SIGA-GET Rating)創下52周新高。該公司股價一度高達2300美元，最新報22.26美元，成交量為250343股。該股此前收盤報19.47美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, TheStreet downgraded shares of SIGA Technologies from a "b" rating to a "c+" rating in a research report on Monday, May 23rd.
另外，華爾街在5月23日週一的一份研究報告中將SIGA Technologies的股票評級從“b”下調至“c+”。
SIGA Technologies Trading Up 19.7 %
SIGA Technologies股價上漲19.7%
The stock's fifty day moving average is $13.56 and its two-hundred day moving average is $9.35. The firm has a market cap of $1.69 billion, a P/E ratio of 24.27 and a beta of 0.63.
該股的50日移動均線切入位為13.56美元，200日移動均線切入位為9.35美元。該公司市值為16.9億美元，市盈率為24.27倍，貝塔係數為0.63。
Institutional Trading of SIGA Technologies
SIGA技術的制度性交易
A number of large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC purchased a new stake in SIGA Technologies in the 4th quarter worth $3,517,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of SIGA Technologies during the second quarter worth approximately $3,346,000. Renaissance Technologies LLC increased its holdings in SIGA Technologies by 44.9% during the fourth quarter. Renaissance Technologies LLC now owns 893,504 shares of the company's stock valued at $6,719,000 after buying an additional 276,814 shares during the period. Kempen Capital Management N.V. grew its holdings in SIGA Technologies by 19.5% in the first quarter. Kempen Capital Management N.V. now owns 1,376,982 shares of the company's stock worth $9,763,000 after purchasing an additional 224,423 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in SIGA Technologies in the first quarter worth $1,133,000. 34.52% of the stock is currently owned by institutional investors.
一些大型投資者最近改變了他們在該股的頭寸。AllSpring Global Investments Holdings LLC在第四季度購買了SIGA Technologies價值3,517,000美元的新股份。康納·克拉克和倫恩投資管理有限公司在第二季度購買了價值約3346,000美元的SIGA技術公司的新股票頭寸。復興科技有限責任公司在第四季度增持了SIGA科技公司44.9%的股份。復興科技有限責任公司現在擁有該公司893,504股股票，價值6,719,000美元，在此期間又購買了276,814股。Kempen Capital Management N.V.在第一季度增持了SIGA Technologies 19.5%的股份。Kempen Capital Management N.V.在上個季度又購買了224,423股，現在擁有1,376,982股該公司股票，價值9,763,000美元。最後，希爾斯代爾投資管理公司在第一季度收購了SIGA Technologies的一個新頭寸，價值1,133,000美元。34.52%的股票目前由機構投資者持有。
SIGA Technologies Company Profile
SIGA技術公司簡介
(Get Rating)
(獲取評級)
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
SIGA Technologies，Inc.是一家商業階段的製藥公司，專注於美國的健康安全和傳染病市場。其主導產品是TPOXX，一種口服制劑抗病毒藥物，用於治療由天花病毒引起的人類天花疾病。SIGA Technologies，Inc.與Cipla治療公司建立了戰略合作伙伴關係，以提供持續的創新和獲得主要針對生物療法的抗菌藥物。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on SIGA Technologies (SIGA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於SIGA技術的研究報告(SIGA)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受SIGA技術日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對SIGA Technologies和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
